Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition

In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the “Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT), 2025 Edition.” Unlike conventional phenotype‐based guidelines, this guidance promotes preemptive cancer medicine based on genotype. The guidance establishes standardized criteria for MGPT eligibility, emphasizing its utility in both cancer‐affected and cancer‐free individuals to identify actionable germline pathogenic variants (GPVs). Key recommendations include the integration of gene‐specific curation for variant interpretation and the implementation of structured clinical practice systems for risk management. By providing evidence‐based management strategies for 56 cancer‐susceptibility genes, this guidance facilitates the shift toward genotype‐driven oncology. This digest assists healthcare providers in utilizing MGPT and supports shared decision‐making for patients and their relatives.